Compare Cytokinetics Inc (CYTK) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Northrop Grumman Corporation — how do they compare? Cytokinetics Inc trades at $62.1 (market cap $8.62B), while Northrop Grumman Corporation trades at $480.03 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 8× Cytokinetics Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Northrop Grumman Corporation for 81 Days on average.
| CYTK | NOC | |
|---|---|---|
Market Cap | $8.62B | $68.83B |
Volume | 2,594,626 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $87.26 | $768.02 |
52-Week Low | $54.76 | $473.46 |
Typical Hold Time | 19 Days | 81 Days |
Enterprise Value | $8.72B | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Northrop Grumman (NOC) trades at $479.00, up 1.17% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations, supported by a robust $104.7 billion backlog and expanding defense budgets. Recent news highlights both competitive pressures from Boeing's $20B fighter contract win and positive developments in F-35 radar demand.
The investment outlook remains positive with analyst consensus at $600.62 (25% upside) and 54% buy ratings, though technical indicators suggest near-term pressure. Key risks include contract competition and execution challenges on major programs like the B-21 bomber, while strong cash flow generation and dividend growth provide shareholder support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
